The role of phosphodiesterase 4 in the pathophysiology of atopic dermatitis and the perspective for its inhibition

Emma Guttman-Yassky, Jon Hanifin, Mark Boguniewicz, Andreas Wollenberg, Robert Bissonnette, Vivek Purohit, Iain Kilty, Anna M. Tallman, Michael A. Zielinski

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Atopic dermatitis (AD) is a highly prevalent, chronic inflammatory skin disease that affects children and adults. The pathophysiology of AD is complex and involves skin barrier and immune dysfunction. Many immune cytokine pathways are amplified in AD, including T helper (Th) 2, Th22, Th17 and Th1. Current treatment guidelines recommend topical medications as initial therapy; however, until recently, only two drug classes were available: topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs). Several limitations are associated with these agents. TCSs can cause a wide range of adverse effects, including skin atrophy, telangiectasia, rosacea and acne. TCIs can cause burning and stinging, and the prescribing information lists a boxed warning for a theoretical risk of malignancy. Novel medications with new mechanisms of action are necessary to provide better long-term control of AD. Phosphodiesterase 4 (PDE4) regulates cyclic adenosine monophosphate in cells and has been shown to be involved in the pathophysiology of AD, making it an attractive therapeutic target. Several PDE4 inhibitors are in clinical development for use in the treatment of AD, including crisaborole, which recently became the first topical PDE4 inhibitor approved for treatment of mild to moderate AD. This review will further describe the pathophysiology of AD, explain the possible role of PDE4 in AD and review PDE4 inhibitors currently approved or being investigated for use in AD.

Original languageEnglish (US)
JournalExperimental Dermatology
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Type 4 Cyclic Nucleotide Phosphodiesterase
Atopic Dermatitis
Phosphodiesterase 4 Inhibitors
Skin
Adrenal Cortex Hormones
Drug Labeling
Rosacea
Therapeutics
Telangiectasis
Skin effect
Skin Diseases
Cyclic AMP
Atrophy

Keywords

  • calcineurin inhibitor
  • corticosteroids
  • crisaborole
  • cytokines
  • eczema

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Dermatology

Cite this

Guttman-Yassky, E., Hanifin, J., Boguniewicz, M., Wollenberg, A., Bissonnette, R., Purohit, V., ... Zielinski, M. A. (Accepted/In press). The role of phosphodiesterase 4 in the pathophysiology of atopic dermatitis and the perspective for its inhibition. Experimental Dermatology. https://doi.org/10.1111/exd.13808

The role of phosphodiesterase 4 in the pathophysiology of atopic dermatitis and the perspective for its inhibition. / Guttman-Yassky, Emma; Hanifin, Jon; Boguniewicz, Mark; Wollenberg, Andreas; Bissonnette, Robert; Purohit, Vivek; Kilty, Iain; Tallman, Anna M.; Zielinski, Michael A.

In: Experimental Dermatology, 01.01.2018.

Research output: Contribution to journalArticle

Guttman-Yassky, E, Hanifin, J, Boguniewicz, M, Wollenberg, A, Bissonnette, R, Purohit, V, Kilty, I, Tallman, AM & Zielinski, MA 2018, 'The role of phosphodiesterase 4 in the pathophysiology of atopic dermatitis and the perspective for its inhibition', Experimental Dermatology. https://doi.org/10.1111/exd.13808
Guttman-Yassky, Emma ; Hanifin, Jon ; Boguniewicz, Mark ; Wollenberg, Andreas ; Bissonnette, Robert ; Purohit, Vivek ; Kilty, Iain ; Tallman, Anna M. ; Zielinski, Michael A. / The role of phosphodiesterase 4 in the pathophysiology of atopic dermatitis and the perspective for its inhibition. In: Experimental Dermatology. 2018.
@article{29a8e2d9426941259de84472dfa015fc,
title = "The role of phosphodiesterase 4 in the pathophysiology of atopic dermatitis and the perspective for its inhibition",
abstract = "Atopic dermatitis (AD) is a highly prevalent, chronic inflammatory skin disease that affects children and adults. The pathophysiology of AD is complex and involves skin barrier and immune dysfunction. Many immune cytokine pathways are amplified in AD, including T helper (Th) 2, Th22, Th17 and Th1. Current treatment guidelines recommend topical medications as initial therapy; however, until recently, only two drug classes were available: topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs). Several limitations are associated with these agents. TCSs can cause a wide range of adverse effects, including skin atrophy, telangiectasia, rosacea and acne. TCIs can cause burning and stinging, and the prescribing information lists a boxed warning for a theoretical risk of malignancy. Novel medications with new mechanisms of action are necessary to provide better long-term control of AD. Phosphodiesterase 4 (PDE4) regulates cyclic adenosine monophosphate in cells and has been shown to be involved in the pathophysiology of AD, making it an attractive therapeutic target. Several PDE4 inhibitors are in clinical development for use in the treatment of AD, including crisaborole, which recently became the first topical PDE4 inhibitor approved for treatment of mild to moderate AD. This review will further describe the pathophysiology of AD, explain the possible role of PDE4 in AD and review PDE4 inhibitors currently approved or being investigated for use in AD.",
keywords = "calcineurin inhibitor, corticosteroids, crisaborole, cytokines, eczema",
author = "Emma Guttman-Yassky and Jon Hanifin and Mark Boguniewicz and Andreas Wollenberg and Robert Bissonnette and Vivek Purohit and Iain Kilty and Tallman, {Anna M.} and Zielinski, {Michael A.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1111/exd.13808",
language = "English (US)",
journal = "Experimental Dermatology",
issn = "0906-6705",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - The role of phosphodiesterase 4 in the pathophysiology of atopic dermatitis and the perspective for its inhibition

AU - Guttman-Yassky, Emma

AU - Hanifin, Jon

AU - Boguniewicz, Mark

AU - Wollenberg, Andreas

AU - Bissonnette, Robert

AU - Purohit, Vivek

AU - Kilty, Iain

AU - Tallman, Anna M.

AU - Zielinski, Michael A.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Atopic dermatitis (AD) is a highly prevalent, chronic inflammatory skin disease that affects children and adults. The pathophysiology of AD is complex and involves skin barrier and immune dysfunction. Many immune cytokine pathways are amplified in AD, including T helper (Th) 2, Th22, Th17 and Th1. Current treatment guidelines recommend topical medications as initial therapy; however, until recently, only two drug classes were available: topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs). Several limitations are associated with these agents. TCSs can cause a wide range of adverse effects, including skin atrophy, telangiectasia, rosacea and acne. TCIs can cause burning and stinging, and the prescribing information lists a boxed warning for a theoretical risk of malignancy. Novel medications with new mechanisms of action are necessary to provide better long-term control of AD. Phosphodiesterase 4 (PDE4) regulates cyclic adenosine monophosphate in cells and has been shown to be involved in the pathophysiology of AD, making it an attractive therapeutic target. Several PDE4 inhibitors are in clinical development for use in the treatment of AD, including crisaborole, which recently became the first topical PDE4 inhibitor approved for treatment of mild to moderate AD. This review will further describe the pathophysiology of AD, explain the possible role of PDE4 in AD and review PDE4 inhibitors currently approved or being investigated for use in AD.

AB - Atopic dermatitis (AD) is a highly prevalent, chronic inflammatory skin disease that affects children and adults. The pathophysiology of AD is complex and involves skin barrier and immune dysfunction. Many immune cytokine pathways are amplified in AD, including T helper (Th) 2, Th22, Th17 and Th1. Current treatment guidelines recommend topical medications as initial therapy; however, until recently, only two drug classes were available: topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs). Several limitations are associated with these agents. TCSs can cause a wide range of adverse effects, including skin atrophy, telangiectasia, rosacea and acne. TCIs can cause burning and stinging, and the prescribing information lists a boxed warning for a theoretical risk of malignancy. Novel medications with new mechanisms of action are necessary to provide better long-term control of AD. Phosphodiesterase 4 (PDE4) regulates cyclic adenosine monophosphate in cells and has been shown to be involved in the pathophysiology of AD, making it an attractive therapeutic target. Several PDE4 inhibitors are in clinical development for use in the treatment of AD, including crisaborole, which recently became the first topical PDE4 inhibitor approved for treatment of mild to moderate AD. This review will further describe the pathophysiology of AD, explain the possible role of PDE4 in AD and review PDE4 inhibitors currently approved or being investigated for use in AD.

KW - calcineurin inhibitor

KW - corticosteroids

KW - crisaborole

KW - cytokines

KW - eczema

UR - http://www.scopus.com/inward/record.url?scp=85058312582&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058312582&partnerID=8YFLogxK

U2 - 10.1111/exd.13808

DO - 10.1111/exd.13808

M3 - Article

C2 - 30332502

AN - SCOPUS:85058312582

JO - Experimental Dermatology

JF - Experimental Dermatology

SN - 0906-6705

ER -